State Street’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $105M | Buy |
5,021,441
+718,395
| +17% | +$16.2M | ﹤0.01% | 1351 |
|
|
2025
Q4 | $99M | Buy |
4,303,046
+610,559
| +17% | +$20.1M | ﹤0.01% | 1362 |
|
|
2025
Q3 | $111M | Buy |
3,692,487
+1,120,247
| +44% | +$33.6M | ﹤0.01% | 1275 |
|
|
2025
Q2 | $93.5M | Sell |
2,572,240
-46,250
| -2% | -$1.67M | ﹤0.01% | 1341 |
|
|
2025
Q1 | $94.8M | Sell |
2,618,490
-104,134
| -4% | -$4.33M | ﹤0.01% | 1292 |
|
|
2024
Q4 | $115M | Buy |
2,722,624
+58,547
| +2% | +$2.9M | ﹤0.01% | 1263 |
|
|
2024
Q3 | $148M | Sell |
2,664,077
-33,024
| -1% | -$1.68M | 0.01% | 1096 |
|
|
2024
Q2 | $111M | Sell |
2,697,101
-154,149
| -5% | -$6.58M | ﹤0.01% | 1195 |
|
|
2024
Q1 | $133M | Sell |
2,851,250
-401,252
| -12% | -$18.9M | 0.01% | 1131 |
|
|
2023
Q4 | $156M | Buy |
3,252,502
+684,644
| +27% | +$26.5M | 0.01% | 1002 |
|
|
2023
Q3 | $91.5M | Buy |
2,567,858
+102,408
| +4% | +$4.06M | 0.01% | 1233 |
|
|
2023
Q2 | $114M | Sell |
2,465,450
-280,257
| -10% | -$13M | 0.01% | 1130 |
|
|
2023
Q1 | $110M | Sell |
2,745,707
-197,060
| -7% | -$8.46M | 0.01% | 1118 |
|
|
2022
Q4 | $136M | Buy |
2,942,767
+383,223
| +15% | +$15.1M | 0.01% | 973 |
|
|
2022
Q3 | $106M | Buy |
2,559,544
+102,236
| +4% | +$5.25M | 0.01% | 1077 |
|
|
2022
Q2 | $147M | Buy |
2,457,308
+508,624
| +26% | +$31.3M | 0.01% | 916 |
|
|
2022
Q1 | $142M | Buy |
1,948,684
+269,843
| +16% | +$18.8M | 0.01% | 1069 |
|
|
2021
Q4 | $141M | Buy |
1,678,841
+204,976
| +14% | +$16.7M | 0.01% | 1043 |
|
|
2021
Q3 | $133M | Buy |
1,473,865
+102,990
| +8% | +$9.31M | 0.01% | 1060 |
|
|
2021
Q2 | $131M | Sell |
1,370,875
-239,964
| -15% | -$25M | 0.01% | 1094 |
|
|
2021
Q1 | $183M | Sell |
1,610,839
-65,460
| -4% | -$8.91M | 0.01% | 832 |
|
|
2020
Q4 | $232M | Sell |
1,676,299
-140,693
| -8% | -$16.7M | 0.01% | 700 |
|
|
2020
Q3 | $149M | Sell |
1,816,992
-161,252
| -8% | -$13.4M | 0.01% | 786 |
|
|
2020
Q2 | $155M | Sell |
1,978,244
-251,107
| -11% | -$16.6M | 0.01% | 750 |
|
|
2020
Q1 | $99M | Buy |
2,229,351
+30,604
| +1% | +$1.59M | 0.01% | 864 |
|
|
2019
Q4 | $93.9M | Buy |
2,198,747
+87,859
| +4% | +$3.62M | 0.01% | 1089 |
|
|
2019
Q3 | $90.3M | Sell |
2,110,888
-8,844
| -0.4% | -$480K | 0.01% | 1067 |
|
|
2019
Q2 | $135M | Buy |
2,119,732
+198,021
| +10% | +$12.6M | 0.01% | 862 |
|
|
2019
Q1 | $133M | Sell |
1,921,711
-129,928
| -6% | -$7.42M | 0.01% | 848 |
|
|
2018
Q4 | $89.2M | Buy |
2,051,639
+339,115
| +20% | +$18.5M | 0.01% | 968 |
|
|
2018
Q3 | $131M | Buy |
1,712,524
+63,773
| +4% | +$5.19M | 0.01% | 901 |
|
|
2018
Q2 | $127M | Sell |
1,648,751
-368,544
| -18% | -$23.8M | 0.01% | 886 |
|
|
2018
Q1 | $103M | Buy |
2,017,295
+420,776
| +26% | +$21.2M | 0.01% | 985 |
|
|
2017
Q4 | $74M | Buy |
1,596,519
+81,448
| +5% | +$3.99M | 0.01% | 1195 |
|
|
2017
Q3 | $80.7M | Sell |
1,515,071
-21,214
| -1% | -$1.26M | 0.01% | 1107 |
|
|
2017
Q2 | $95.4M | Buy |
1,536,285
+270,729
| +21% | +$16.3M | 0.01% | 984 |
|
|
2017
Q1 | $85.8M | Sell |
1,265,556
-131,633
| -9% | -$10M | 0.01% | 1035 |
|
|
2016
Q4 | $98.2M | Sell |
1,397,189
-80,247
| -5% | -$5.69M | 0.01% | 919 |
|
|
2016
Q3 | $105M | Buy |
1,477,436
+208,750
| +16% | +$13.3M | 0.01% | 854 |
|
|
2016
Q2 | $62M | Sell |
1,268,686
-15,638
| -1% | -$1.01M | 0.01% | 1076 |
|
|
2016
Q1 | $81.3M | Buy |
1,284,324
+300,901
| +31% | +$19.7M | 0.01% | 927 |
|
|
2015
Q4 | $110M | Buy |
983,423
+126,542
| +15% | +$12.7M | 0.01% | 791 |
|
|
2015
Q3 | $82.5M | Buy |
856,881
+19,831
| +2% | +$2.27M | 0.01% | 907 |
|
|
2015
Q2 | $85.7M | Buy |
837,050
+317,063
| +61% | +$24.6M | 0.01% | 944 |
|
|
2015
Q1 | $32.3M | Sell |
519,987
-5,794
| -1% | -$322K | ﹤0.01% | 1496 |
|
|
2014
Q4 | $23.1M | Buy |
525,781
+146,916
| +39% | +$6.73M | ﹤0.01% | 1700 |
|
|
2014
Q3 | $21.4M | Buy |
378,865
+286,995
| +312% | +$14.4M | ﹤0.01% | 1696 |
|
|
2014
Q2 | $4.12M | Buy |
91,870
+27,889
| +44% | +$1.15M | ﹤0.01% | 2697 |
|
|
2014
Q1 | $3.13M | Buy |
+63,981
| New | +$3.29M | ﹤0.01% | 2828 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
State Street's RARE Position: Q1 2026 in Review
State Street increased its Ultragenyx Pharmaceutical (RARE) stake by 17% in Q1 2026, buying an estimated $16.2M and bringing the position to 5,021,441 shares worth $105M. The position accounts for ﹤0.01% of the portfolio, ranked #1351.
State Street first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $232M in Q4 2020. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- State Street held 5,021,441 shares of Ultragenyx Pharmaceutical worth $105M as of Q1 2026.
- State Street bought 718,395 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $16.2M.
- Ultragenyx Pharmaceutical made up ﹤0.01% of State Street's portfolio in Q1 2026, its #1351 holding.
- State Street first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
- State Street's Ultragenyx Pharmaceutical position peaked at $232M in Q4 2020.
- 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.